دورية أكاديمية
1105TiP - DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
| العنوان: | 1105TiP - DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM) |
|---|---|
| المؤلفون: | Trudel, S., Nooka, A., Fecteau, D., Talekar, M., Jewell, R.C., Williams, D., Evans, J., Opalinska, J. |
| المصدر: | In Annals of Oncology October 2019 30 Supplement 5:v447-v447 |
| قاعدة البيانات: | ScienceDirect |
| تدمد: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz251.039 |